CFO transition
Vertex Pharmaceuticals Incorporated CFO transition: Jonathan Poole to succeed Charles F. Wagner, Jr.
Vertex Pharmaceuticals Incorporated reported in a Form 8-K filed September 1, 2026 that Jonathan Poole will succeed Charles F. Wagner, Jr. as Executive Vice President and Chief Financial Officer, effective January 1, 2027.
In the filing's words
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Vertex Pharmaceuticals Incorporated (VRTX) |
|---|---|
| Event | Transition |
| Incoming | Jonathan Poole |
| Outgoing | Charles F. Wagner, Jr. |
| Title in the filing | Executive Vice President and Chief Financial Officer |
| Effective | January 1, 2027 |
| 8-K filed | September 1, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Senior Vice President, Finance, Vertex Pharmaceuticals Incorporated |
| SEC CIK | 0000875320 |
Vertex Pharmaceuticals Incorporated reported this change in a Form 8-K, Item 5.02, filed September 1, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Jonathan Poole? Send a correction with the primary source.